A Phase II, Single-arm, Multicenter Clinical Study of Adebrelimab Combined With Chemotherapy and Apatinib as First-line Treatment for Unresectable Locally Advanced or Metastatic Pulmonary Neuroendocrine Tumors
Latest Information Update: 13 Jan 2025
Price :
$35 *
At a glance
- Drugs Adebrelimab (Primary) ; Carboplatin; Cisplatin; Etoposide; Rivoceranib
- Indications Brain metastases; Carcinoid tumour; Neuroendocrine carcinoma; Neuroendocrine tumours; Small cell lung cancer
- Focus Therapeutic Use
- 13 Jan 2025 New trial record